Primary central nervous system lymphoma in daily practice and the role of autologous stem cell transplantation in relapsed disease: A retrospective multicenter study

Simple item page
dc.contributor.authorErkurt M.A.
dc.contributor.authorBerber I.
dc.contributor.authorTekgündüz E.
dc.contributor.authorDogu M.H.
dc.contributor.authorKorkmaz S.
dc.contributor.authorDemir C.
dc.contributor.authorYilmaz M.
dc.contributor.authorAkay O.M.
dc.contributor.authorPala C.
dc.contributor.authorBilen Y.
dc.contributor.authorKaya E.
dc.contributor.authorSari I.
dc.contributor.authorSencan M.
dc.contributor.authorKuku I.
dc.contributor.authorAltuntaş F.
dc.contributor.authorDal M.S.
dc.contributor.authorAydogdu I.
dc.date.accessioned2025-04-10T11:09:27Z
dc.date.available2025-04-10T11:09:27Z
dc.date.issued2016
dc.description.abstractWe investigated the course of 54 patients presenting with primary central nervous system lymphoma, who were treated in daily practice. The patients were treated with chemotherapy and/or radiotherapy and/or intrathecal chemotherapy. At a median follow-up period of 23 months (range 1-71), median relapse-free survival (RFS) and overall survival (OS) were not reached. Estimated 2-year RFS and OS rates were 42% and 48%, respectively. Ten relapsed PCNSL patients underwent ASCT. Complete remission rate of these patients was 40%, with 20% treatment-related mortality. Estimated 2-year RFS and OS rates were 37% and 40%, respectively. The prognosis of patients with PCNSL, who received off-study treatment, is still dismal. © 2016 Elsevier Ltd.
dc.identifier.DOI-ID10.1016/j.transci.2016.01.018
dc.identifier.urihttp://hdl.handle.net/20.500.14701/48748
dc.publisherElsevier Ltd
dc.titlePrimary central nervous system lymphoma in daily practice and the role of autologous stem cell transplantation in relapsed disease: A retrospective multicenter study
dc.typeArticle

Files

Collections

Scopus Koleksiyonu